SecBot SecBot

ALGS

Aligos Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001799448 Biotech & Drug Discovery
$4.74 +0.09 (+1.94%)
Oct 27 4:00 PM ET · prev $4.65
Market cap
$29.8M
Nano cap
Median target
🔒 Subscribers only
Next earnings
Nov 4
in 8 days
1 year
−49.1%
from $9.32 · Oct 28
30 days
−14.4%
from $5.54
52-week range
$4.08–13.30
−64% from high · low Jul 24
Avg volume 20D
33.3K
shares / day
Short interest
707.5K
≈11.3% of shares · −0.2%
Days to cover
21.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·Next Earnings date, Nov 4, 2026
Strongest MIXED Aligos Therapeutics reported Q2 2026 financial results with a net loss of $1.5M ($-0.14/share), a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 3 trimmed or exited.

  • Short sellersSTEADY

    Short interest −0.2% to 707.5K shares. 21.7 days to cover, ≈11.3% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
D. E. Shaw & Co., Inc.DOUBLED66,463$383.5K
UBS Group AGADD59,986$346.1K
BlackRock, Inc.DOUBLED30,292$174.8K
RENAISSANCE TECHNOLOGIES LLCNEAR_EXIT10,800$62.3K
Federation des caisses Desjardins du QuebecDOUBLED4,650$26.8K
JPMORGAN CHASE & COTRIM344$1.9K
WELLS FARGO & COMPANY/MNNEAR_EXIT100$577.00
BANK OF AMERICA CORP /DE/DOUBLED229,754$1.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
May 28, 2026Lake Street
INITIATE
INITIATEBuy
May 21, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 25, 2026
Scopa James Paul
Director
AWARD5,860 sh
Jun 25, 2026
Nuechterlein Carole
Director
AWARD5,860 sh
Jun 25, 2026
Hirth Peter
Director
AWARD5,860 sh
Jun 25, 2026
Martell Bridget A
Director
AWARD5,860 sh
Jun 25, 2026
Preston Heather
Director
AWARD5,860 sh
Jun 25, 2026
Chavez Margarita
Director
AWARD5,860 sh
Mar 9, 2026
Symons Julian A.
See Remarks
AWARD23,310 sh
Mar 9, 2026
Aneja Nikhil
Principal Accounting Officer
AWARD9,450 sh

Earnings setup

Estimates
Nov 4
reports in 8 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
707,471
shares short
-0.2%
vs prior settlement
21.7
days to cover
≈11.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 Other
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL
Aug 6, 2026 SEC
Aligos Therapeutics reported Q2 2026 financial results with a net loss of $1.5M ($-0.14/share), a significant…
8-K — Impact 5/10
Jun 30, 2026 Inst.
D. E. Shaw & — DOUBLED
66,463 shares ($383.5K)
Jun 30, 2026 Inst.
UBS Group AG — ADD
59,986 shares ($346.1K)
Jun 26, 2026 SEC
Aligos Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting, where stockholders approved an…
8-K — Impact 3/10
Jun 25, 2026 Insider
Scopa James Paul was granted 5,860 shares
Director
Jun 25, 2026 Insider
Nuechterlein Carole was granted 5,860 shares
Director
Jun 25, 2026 Insider
Hirth Peter was granted 5,860 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
ALGS Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 5, 2026
Press release
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company…
Aug 12, 2026
FDA
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company…
Aug 6, 2026
Earnings
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology…
Aug 6, 2026
Earnings date
ALGS Q2 2026 Earnings Scheduled — 2026-08-06
Aug 4, 2026
Earnings date
ALGS Q2 2026 Earnings Scheduled — 2026-08-04

SecBot reports

4 filings · 4 press releases · 1 bullish · 0 bearish · 2 mixed · 1 neutral
All ALGS filing & press-release reports (8)